KRAS and non-small cell lung carcinoma: We selected the MOR KRAS mutant NSCLC cell line because its growth rate is relatively insensitive to MEK or ERK inhibitor treatment (S1A Fig) even at concentrations that show significant pathway inhibition (S1B Fig).